Gossamer Bio submits first NDA, for seralutinib in PAH, to FDA
The September 2026 filing could trigger up to $125 million more in committed financing once FDA accepts it, as the company reported third quarter results.
SEC filing
5 stories
The September 2026 filing could trigger up to $125 million more in committed financing once FDA accepts it, as the company reported third quarter results.
SEC filing
The trial was terminated after enrollment declined and remaining participants had already been on study for more than three years, the registry record states.
ClinicalTrials.gov
The company filed its application with the FDA in September 2026, backed by Phase 3 PROSERA and Phase 2 TORREY data.
SEC filing
The seralutinib developer named the Adiumentum Capital founder as a Class III director effective September 16, 2026.
SEC filing
The San Diego biotechnology company reported $25 million sold so far to 38 investors, with $125 million remaining under the notice.
SEC filing